{
  "docId": "019de073-e127-72a6-a95e-e417b3ed6013",
  "docSlug": "0a46c3e8bf46013b57087adaac7a88f4",
  "documentTitle": "Xeris Biopharma | Investor Presentation Deck | 11 slides",
  "authorId": "xeris-biopharma",
  "authorName": "Xeris Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 11,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "Clinical trial data (XP-8121-108) comparing subcutaneous (SC) vs oral (PO) administration.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-e127-72a6-a95e-e417b3ed6013/8",
  "deckHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013",
  "deckJsonHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013.json",
  "deckAnchorHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.68,
        "w": 0.62,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "chart",
      "text": "Line chart showing T4 concentration over 28 days for different doses of XP-8121 and Synthroid.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56e25a95-a2ed-423f-b3f9-85e898c47d4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.68,
        "w": 0.3,
        "x": 0.67,
        "y": 0.21
      },
      "kind": "list",
      "text": "Synthroid PO 600 ug exhibits a rapid rise in levothyroxine levels followed by a rapid decline. XP-8121 SC exhibits a lower maximum concentration (Cmax), longer time to maximum concentration (Tmax) with sustained exposure profile relative to Synthroid PO administration. Confirmation of dose proportional exposure with ascending doses of XP-8121. No major safety concerns were identified.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3157f3a-1344-4f7f-9131-9043f290c443",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Baseline Adjusted T4 Concentration by Time Profile Day 1 to Day 28 Following Single Dose Administration (XP-8121-108)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f65367ad-dc8a-4d14-9813-9f4d52800471",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 7,
      "beatId": "618cb87d-97ad-4b2e-bac2-934e0c49b76f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The traction and appendix methodology slides present the solution and clinical results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f2a7b48c-76f2-4134-b42d-4dd72dd13ce4",
      "evidence": "The appendix methodology and key takeaways slides present the golden circle.",
      "position": 1,
      "objective": "How does XeriSol™ Levothyroxine work and what are the benefits?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}